PGNY Form 144 Filing Details: 599 Shares from Restricted Stock Vesting
Rhea-AI Filing Summary
Form 144 filing for Progyny, Inc. (PGNY) reports a proposed sale of 599 shares of common stock through Fidelity Brokerage Services on 09/04/2025 with an aggregate market value of $14,094.47. The filing shows these shares were acquired the same day as restricted stock vesting and were paid as compensation. The issuer has 85,982,409 shares outstanding. The filing also discloses a prior sale by the same person: 2,398 shares sold on 08/28/2025 for $55,058.08, identified as seller Allison C. Swartz. The form includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider proposes a small sale following restricted stock vesting; transaction size is minor versus outstanding shares.
The filing documents a proposed sale of 599 shares valued at $14,094.47 arising from restricted stock vesting and designated as compensation. From an investor-impact perspective, this is routine insider liquidity after vesting rather than a corporate action. The earlier reported sale of 2,398 shares for $55,058.08 indicates ongoing disposition activity by the same individual. Given the issuer's 85,982,409 shares outstanding, these transactions are immaterial to capitalization and unlikely to affect market dynamics on their own. The filing complies with Rule 144 disclosure requirements and includes the standard certification about material nonpublic information.
TL;DR: Disclosure is procedurally complete; sales stem from vested compensation and include required representations.
The Form 144 provides requisite details: broker, number of shares, acquisition method (restricted stock vesting), payment nature (compensation), and past three-month sales by the filer. From a governance standpoint, this is a routine compliance filing following equity vesting. The presence of prior sales by the same individual is transparent and appropriately disclosed. No indications of trading-plan dates or 10b5-1 reliance are provided in the document. The filing's signature statement reiterates the filer’s attestation regarding material nonpublic information, fulfilling procedural expectations.